English Bcr-Abl tyrosine-kinase inhibitor Cited by user Hinemash6 on 05 Nov 2010 Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML).